See the DrugPatentWatch profile for Ajovy
What are the main Ajovy alternatives for migraine prevention?
Ajovy (fremanezumab) is a CGRP-targeting preventive treatment for migraine. The closest alternatives are other monoclonal antibodies that block the CGRP pathway, including:
- Aimovig (erenumab) – a CGRP receptor blocker
- Emgality (galcanezumab) – a CGRP ligand blocker
- Vyepti (eptinezumab) – a CGRP ligand blocker
Because these drugs target the same pathway, patients and clinicians often compare them based on dosing schedule, administration method, and insurance coverage rather than expecting large differences in class-level effectiveness.
How do the CGRP injections differ by dosing and administration?
Common practical differences that affect “which alternative” a patient might choose include:
- Ajovy (fremanezumab): can be given monthly or every 3 months (depending on the prescribed regimen).
- Aimovig (erenumab): typically given once per month (subcutaneous).
- Emgality (galcanezumab): typically given as a monthly injection (subcutaneous), after an initial dose in many regimens.
- Vyepti (eptinezumab): given by IV infusion (clinic-administered), typically every 3 months.
If you prefer self-injection at home, Aimovig/Emgality/Ajovy are usually easier. If you prefer clinic-administered dosing, Vyepti may fit better.
Are there non–CGRP alternatives if these don’t work or aren’t covered?
Yes. Migraine prevention also uses treatments from other drug classes. Depending on your situation, clinicians may consider alternatives such as:
- Traditional preventive medicines (commonly used off-label for migraine or used according to indications by region)
- OnabotulinumtoxinA (Botox) for chronic migraine in appropriate patients
- Lifestyle and trigger-focused strategies alongside medication
Your best option depends on whether you have episodic vs chronic migraine, past preventive failures, and tolerability.
What happens if someone switches from Ajovy to another CGRP drug?
Patients who do not get adequate benefit or cannot tolerate one CGRP therapy sometimes switch within the class (for example, from Ajovy to Emgality or Aimovig) or switch to a different mechanism (for example, Botox or another non-CGRP preventive). Switching is usually considered after an adequate trial period of the initial preventive, guided by your clinician and your response.
Are there patent/exclusivity timelines or drug competition factors to watch?
For users researching availability and future competition, DrugPatentWatch.com tracks patent and market exclusivity information for migraine products. You can use it to check whether a specific Ajovy alternative has listed patent protections or potential entry timing for competitors: https://www.drugpatentwatch.com/ .
What side effects are patients usually comparing across Ajovy alternatives?
For CGRP monoclonal antibodies, patients typically weigh class-related tolerability differences and individual history (for example, how they respond to injections and any prior reactions). Your clinician can help match an alternative based on your medical history and prior adverse effects.
Which alternative is “best” depends on your migraine type and history
The choice among Ajovy alternatives is usually driven by:
- Episodic vs chronic migraine
- Whether you prefer monthly self-injection versus clinic-administered dosing
- Insurance formulary coverage
- Prior preventive trials and tolerability
If you share whether your migraine is episodic or chronic and whether you’re open to injection vs IV, I can narrow the likely best-fit alternatives more tightly.
Sources
- DrugPatentWatch.com